Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medtronic CoreValve Meets Targets In Extreme-Risk Group; Panel Will Not Be Needed, FDA Says

This article was originally published in The Gray Sheet

Executive Summary

The firm now expects to gain approval for the extreme-risk indication of its transcatheter aortic heart valve months earlier than earlier predicted following well-received pivotal trial data reported last week at the Transcatheter Cardiovascular Therapeutics meeting.

Advertisement

Related Content

Medtronic Touts New Products, Advantages Of TAVR In Post-CABG Patients
TAVR Performance Sustained In Long-Term Data
News Briefs: Medtronic’s CoreValve Approval; J&J Dx Unit Set For Sale; Google’s Glucometer Contact Lens
Renal Denervation Downer: Medtronic’s Pivotal Trial Misses Efficacy Endpoint
Renal Denervation Downer: Medtronic’s Pivotal Trial Misses Efficacy Endpoint
TAVR Competitors Put Pressure On Edwards To Deliver On New Growth Drivers
Edwards Finds Transcatheter Valve Adoption In U.S. Slower Than Expected
First PARTNER II Results Show Progress With Edwards’ TAVR Technology
Edwards Can Proceed With Next-Gen Transcatheter Valve Study

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

MT032561

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel